stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) Return on invested capital
Ascendis Pharma A/S's return on invested capital over the twelve months to 30 June 2026 was 15.1%, up 106.7 percentage points from fiscal 2025 (−91.7%). Over the past ten years it has ranged from −84,748.4% (fiscal 2023) to 0.00% (fiscal 2017); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −91.7% | (0.61) |
| FY2024 | −91.0% | 84,657.31 |
| FY2023 | −84,748.4% | (83,780.24) |
| FY2022 | −968.1% | (874.66) |
| FY2021 | −93.5% | 1.35 |
| FY2020 | −94.8% | 303.06 |
| FY2019 | −397.9% | 4,022.81 |
| FY2018 | −4,420.7% | (4,420.67) |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 3,844.07 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| EXEL Exelixis, Inc. compare | 66.6% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 59.4% |
| HALO Halozyme Therapeutics, Inc. compare | 19.9% |
| ASND Ascendis Pharma A/S | 15.1% |
| JAZZ Jazz Pharmaceuticals PLC compare | 3.86% |
| BBIO BridgeBio Pharma, Inc. compare | 0.00% |
| SMMT Summit Therapeutics PLC compare | 0.00% |
| BNTX BioNTech SE Sponsored ADR compare | −34.3% |
| INSM Insmed, Inc. compare | −247.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on ASND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement